Literature DB >> 2182506

Pathology and breast screening.

C W Elston1, I O Ellis.   

Abstract

Following the publication of the Forrest Report in 1986, the Department of Health has established a national breast screening programme in the United Kingdom, to be fully implemented in 1990. Women aged between 50 and 64 years will be invited to undergo mammographic screening on a 3-year cycle. Funding has been allocated on the basis that a basic screening unit will serve a population of half a million and that specialist assessment centres will cover the work from up to three basic units. The organization of screening services requires careful planning and close cooperation between specialties; histopathologists and cytopathologists must ensure that they are fully consulted. There will be a considerable impact on laboratories and appropriate funding and manpower are required for the additional workload. Pathologists will be asked to provide a specialist service in the interpretation of diagnostic samples from such techniques as fine needle aspiration cytology and needle localization biopsies. Diagnostic difficulties will be encountered in the assessment of impalpable screen-detected abnormalities and special training in breast screening is being provided. To ensure the success of the programme a national quality assurance scheme is being implemented. This will include validation of pathology data through regional coordinators.

Entities:  

Mesh:

Year:  1990        PMID: 2182506     DOI: 10.1111/j.1365-2559.1990.tb01078.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  9 in total

1.  Implications on laboratory workload of breast cancer screening.

Authors:  B Green; I W McDicken; L S Turnbull
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

Review 2.  Laboratory handling of impalpable breast lesions: a review.

Authors:  J S Armstrong; J D Davies
Journal:  J Clin Pathol       Date:  1991-02       Impact factor: 3.411

3.  The expression of Ras-GTPase activating protein SH3 domain-binding proteins, G3BPs, in human breast cancers.

Authors:  Juliet French; Renée Stirling; Michael Walsh; Hendrick Daniel Kennedy
Journal:  Histochem J       Date:  2002-05

4.  Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.

Authors:  M M Vleugel; A E Greijer; A Shvarts; P van der Groep; M van Berkel; Y Aarbodem; H van Tinteren; A L Harris; P J van Diest; E van der Wall
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

5.  Expression of MUC2 epithelial mucin in breast carcinoma.

Authors:  M D Walsh; M A McGuckin; P L Devine; B G Hohn; R G Wright
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

6.  The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression.

Authors:  Pang-Kuo Lo; Ji Shin Lee; Xiaohui Liang; Saraswati Sukumar
Journal:  Cell Signal       Date:  2016-07-01       Impact factor: 4.315

7.  Proliferative indices and oncoprotein expression in benign and malignant breast biopsies.

Authors:  S T Brower; P I Tartter; S Ahmed; C M Brusco; K Bossolt; C Hayden; I Bleiweiss
Journal:  Ann Surg Oncol       Date:  1995-09       Impact factor: 5.344

8.  Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.

Authors:  R Michalides; H van Tinteren; A Balkenende; J B Vermorken; J Benraadt; J Huldij; P van Diest
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

9.  A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer.

Authors:  R Michalides; P Hageman; H van Tinteren; L Houben; E Wientjens; R Klompmaker; J Peterse
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.